Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
PalanorPalanor

Company Dossier · Health Care

Dentsply Sirona

XRAYNasdaqWILMINGTON, US-DE, USSmall capWebsite ↗
  • MidCap 400

What Dentsply Sirona is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $3.64 billion, down 0.8% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.14 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.18 billion, up 20% from a year earlier.SEC EDGAR filings (XBRL)
  • Long-term debt issued in the fiscal year to December 31, 2025: $0.55 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 6, 2026): sentiment -0.20 on a −1 to +1 scale (negative), confidence 0.70 of 1.Palanor Discourse
  • Latest annual report (filed February 26, 2026): 0 risk factors added, 6 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net buyers in Q2 2026: $0.6 million on the open market.SEC Form 4
  • 373 institutional managers reported a position at June 30, 2026 (−12 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 4 (12 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Dentsply Sirona yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Dentsply Sirona: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$0.14BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Dentsply Sirona: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Dentsply Sirona: revenue, trailing twelve months

$ billions, from SEC filings

$3.6BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Dentsply Sirona: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.00BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Dentsply Sirona: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Dentsply Sirona: guidance raised minus lowered

Guidance Ledger statements by quarter

−2.0Data to Dec 2025
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Dentsply Sirona: earnings call sentiment

Palanor Discourse score per call, −1 to +1

−0.20Data to Aug 2026
ImageDataPalanor calculation
Business

Dentsply Sirona: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.70Data to Aug 2026
ImageDataPalanor calculation
Business

Dentsply Sirona: risk factors added per annual report

New Item 1A risk factors in each 10-K

0.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Dentsply Sirona: H-1B filings certified

Labor Condition Applications by quarter received

4.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Dentsply Sirona: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

$0.6MData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Dentsply Sirona: institutional holders

Managers reporting a position on Form 13F, by quarter

373.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

In the news

Headlines that name Dentsply Sirona, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
1 headlines
100% positive · 0% negative
90 days
1 headlines
100% positive · 0% negative

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 12, 2026Trademark
  2. Oct 9, 20268-K
  3. Oct 6, 2026Patent
  4. Sep 8, 2026Patent
  5. Sep 8, 2026Patent
  6. Sep 1, 2026Patent
  7. Sep 1, 2026Patent
  8. Jun 11, 20268-K
  9. Jun 4, 20268-K
  10. Feb 26, 202610-K
    Annual report (10-K)0 risk factors added, 6 removed
  11. Feb 24, 20268-K
  12. Jan 27, 2026Trademark
  13. Jan 22, 2026Lobbying
    Lobbying report (DENTSPLY SIRONA INC.)fourth_quarter 2025 · $0.0 million
  14. Jan 20, 2026Lobbying
  15. Jan 13, 20268-K
  16. Dec 31, 20258-K
  17. Dec 19, 2025Lobbying
    Lobbying report (FORBES-TATE)fourth_quarter 2025 · $0.1 million
  18. Nov 7, 20258-K
  19. Nov 6, 20258-K
  20. Oct 29, 2025Trademark
  21. Oct 29, 2025Trademark
  22. Oct 18, 2025Lobbying
    Lobbying report (FORBES-TATE)third_quarter 2025 · $0.1 million
  23. Oct 15, 2025Lobbying
    Lobbying report (DENTSPLY SIRONA INC.)third_quarter 2025 · $0.0 million
  24. Oct 3, 20258-K
  25. Sep 19, 20258-K
  26. Jul 21, 20258-K
  27. Jul 18, 2025Lobbying
    Lobbying report (DENTSPLY SIRONA INC.)second_quarter 2025 · $0.1 million
  28. Jul 17, 2025Lobbying
    Lobbying report (FORBES-TATE)second_quarter 2025 · $0.1 million
  29. Jun 12, 20258-K
  30. Jun 12, 20258-K
  31. Jun 4, 20258-K
  32. May 29, 20258-K
  33. May 22, 20258-K
  34. Apr 18, 2025Lobbying
    Lobbying report (FORBES-TATE)first_quarter 2025 · $0.0 million
  35. Mar 19, 20258-K
  36. Feb 27, 202510-K
    Annual report (10-K)1 risk factors added, 2 removed
  37. Feb 6, 20258-K
  38. Nov 7, 20248-K
  39. Feb 29, 202410-K
    Annual report (10-K)2 risk factors added, 5 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Alnylam Pharmaceuticals ALNY$3.7B$0.5BDec 31, 2025
Bruker BRKR$3.5B$0.1BJun 30, 2026
Veeva Systems VEEV$3.5B—Jul 31, 2026
BioMarin Pharmaceutical BMRN$3.4B$0.7BJun 30, 2026
Neurocrine Biosciences NBIX$3.4B$0.6BJun 30, 2026
West Pharmaceutical Services WST$3.3B$0.4BJun 30, 2026
Charles River Laboratories CRL$4.0B$0.4BJun 27, 2026
Mettler Toledo MTD$4.1B$0.9BJun 30, 2026

Identity

SEC CIK
818479
Wikidata
Q834888

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.